I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

In recent years, advances in technology and pharmacology have resulted in a marked increase in the number of outpatient surgeries/procedures.\[[@ref1]\] The number of outpatients and minimally invasive surgeries have increased dramatically in recent years as a result of advancements in surgical technology, economic consideration, and better patient cooperation. Patient cooperation is of prime importance in the field of surgery, for the patient as well as the surgeon, especially under local anesthesia. The major hindrances in the patient cooperation are apprehension toward the treatment, fear, and anxiety. It is the most significant entity, second only to pain.

Many ways have been devised to attain cessation of anxiety and fear, sedation being one of the techniques. In 1845, Connecticut dentist Horace Wells\[[@ref2]\] used nitrous oxide to extract aching tooth. In 1846, a dentist named of William T. G. Morgan\[[@ref2]\] gave sulfur -- ether compound -- to the patient undergoing surgery. Oral sedation is one of the modalities commonly used. Intranasal route is the most recent advance in the administration of sedatives through noninvasive ways. The main advantages being that it is less intimidating for the patient leading to better patient cooperation, smooth conduction of the procedure, and better use of time and resources. The highly vascularized nasal mucosa and the olfactory tissue in direct contact with the central nervous system allow nasally administered drugs to be rapidly transported into the bloodstream and brain, with onsets of action approaching that of intravenous (IV) therapy. It provides large surface area, porous endothelial membrane, high total blood flow, the avoidance of first-pass metabolism, rapid onset, and ready accessibility.\[[@ref3]\] Intranasal dexmedetomidine is the most recent advance in the field of sedation. A study was done in our institute on the efficacy of dexmedetomidine in sedation when given through intranasal route. The focus was on the efficacy of the drug in terms of fear and anxiety levels of the patient undergoing various minor oral surgical procedures.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

After clearance from institutional ethical committee, a total of 25 patients fitting the inclusion and exclusion criteria were selected from the outpatient Department of Oral and Maxillofacial surgery, Saraswati Dental College and Hospital, Lucknow, who volunteered to participate in the study. A written informed consent was obtained from all the patients.

Inclusion criteria {#sec2-1}
------------------

The patients were randomly selected to participate in the study based on the following criteria:

Patients requiring minor oral surgical procedure which was expected to finish within 1½ h operative time.Age group: 18--50 yearsPatients with American Society of Anesthesiologists (ASA) physical status I.

Exclusion criteria {#sec2-2}
------------------

The patients falling in the following category were not selected for this study:

Medically compromisedImmunocompromised patientsPregnant and lactating mothersBody mass index \>27 kg/m^2^\[[@ref3]\]Alcohol consumption in excess of 28 units per week (1 unit = 30 ml)\[[@ref4]\]Chronic sedative or analgesic use, including drug abusersRegular use of or known allergy to dexmedetomidine, paracetamol, nonsteroidal anti-inflammatory drugs, or opioidsPatients with preoperative inflammation at the site of drug administrationUpper respiratory catarrh, rhinitis.

Materials {#sec2-3}
---------

Liquid form in a vial of 1 ml in concentration of 100 μg/ml dexmedetomidine \[[Figure 1](#F1){ref-type="fig"}\]Intranasal atomization device \[[Figure 1](#F1){ref-type="fig"}\] along with 3 ml syringe \[[Figure 2](#F2){ref-type="fig"}\]Pulse oximeterCardiac multipara monitor.

![(a) The drug used with atomizer. (b) Patient about to receive the drug. (c) Patient receiving the atomizer. (d) Patient receiving the drug on the left side. (e) Patient sedated](AMS-9-89-g001){#F1}

![(a) Patient 2 being sedated. (b) Patient sedated](AMS-9-89-g002){#F2}

Methodology {#sec2-4}
-----------

### Preoperative protocol {#sec3-1}

Complete medical history was recorded, and thorough clinical examination of patients was doneAfter selection, the patients were told about the process in detail and counseled.A written detailed informed consent was obtained

The following presedation assessment parameters were also recorded:

Respiratory rateOxygen saturation (SpO~2~)Local nasal examinationHeart rate (HR)Blood pressure (BP).

Dosage

A fresh mixture of the dosage was prepared using 1 ml of dexmedetomidine and adding 0.5 ml of normal saline to make it 1.5 ml solution.

### Operative protocol {#sec3-2}

The drug was administered intranasally half an hour before the surgical procedure. The volume of drug used was recorded. The readings of all the parameters of sedation began 30 min after the drug had been administered. Intranasal sedation status was assessed by Ramsay sedation score and observer\'s assessment of alertness/sedation (OAA/S) scales, every 15 min throughout the procedure \[Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}\]. Ramsay sedation score ranges from 1 to 6, where 1 means that the patient is anxious, agitated, or both and 6 being unresponsive. Whereas the OAA/S ranges from 5 to 1 where 5 means that the patient does not respond to mild prodding or shaking and 1 means responds readily to name spoken in normal tone. HR and SpO~2~ were recorded every 5 min. Similarly, BP and respiratory rate were recorded at 10 min. We started to take the reading after 30 min from the time of the administration of drug.

###### 

Ramsay sedation score

                                                                                        Ramsay sedation score                                                                    
  ------------------------------------------------------------------------------------- ----------------------- ------------ ------------ ------------ ------------ ------------ ------------
  1\. Anxious and agitated or restless, or both                                         2 (8.00)                0 (0.00)     0 (0.00)     0 (0.00)     0 (0.00)     0 (0.00)     11 (44.00)
  2\. Cooperative, oriented, and calm                                                   8 (32.00)               3 (12.00)    0 (0.00)     0 (0.00)     2 (8.00)     12 (48.00)   14 (56.00)
  3\. Responsive to commands only                                                       11 (44.00)              16 (64.00)   10 (40.00)   0 (0.00)     6 (24.00)    13 (52.00)   0 (0.00)
  4\. Exhibiting brisk response to light glabellar tap or loud auditory stimulus        4 (16.00)               6 (24.00)    12 (48.00)   20 (80.00)   15 (60.00)   0 (0.00)     0 (0.00)
  5\. Exhibiting a sluggish response to light glabellar tap or loud auditory stimulus   0 (0.00)                0 (0.00)     3 (12.00)    5 (20.00)    2 (8.00)     0 (0.00)     0 (0.00)
  6\. Unresponsive                                                                      0 (0.00)                0 (0.00)     0 (0.00)     0 (0.00)     0 (0.00)     0 (0.00)     0 (0.00)

###### 

Observer's assessment of alertness/sedation scale

                                                                    OAA/S                                                                         
  ----------------------------------------------------------------- ------------ ------------ ------------ ------------ ------------ ------------ ------------
  5\. Does not respond to mild prodding or shaking                  0 (0.00)     0 (0.00)     0 (0.00)     0 (0.00)     0 (0.00)     0 (0.00)     1 (4.00)
  4\. Responds only after mild prodding or shaking                  1 (4.00)     1 (4.00)     2 (8.00)     0 (0.00)     2 (8.00)     1 (4.00)     0 (0.00)
  3\. Responds only after name is called loudly and/or repeatedly   3 (12.00)    1 (4.00)     4 (16.00)    18 (72.00)   6 (24.00)    11 (44.00)   0 (0.00)
  2\. Lethargic response to name spoken in normal tone              3 (12.00)    17 (68.00)   19 (76.00)   7 (28.00)    17 (68.00)   13 (52.00)   5 (20.00)
  1\. Responds readily to name spoken in normal tone                18 (72.00)   6 (24.00)    0 (0.00)     0 (0.00)     0 (0.00)     0 (0.00)     19 (76.00)

OAA/S=Observer's assessment of alertness/sedation

O[BSERVATIONS AND]{.smallcaps} R[ESULTS]{.smallcaps} {#sec1-3}
====================================================

A randomized study was conducted that included a total of 25 patients, of which 11 were females and 14 were males. The results of the study are expressed in tables and Graphs as medians (range). The primary outcome variable in this study is depth of sedation produced by intranasally administered dexmedetomidine. Secondary variables included respiratory rate, BP, HR, and SpO~2~ \[Tables [1](#T1){ref-type="table"}-[6](#T6){ref-type="table"} and Graphs [1](#F3){ref-type="fig"}-[8](#F10){ref-type="fig"}\].

###### 

Descriptive statistics of heart rate

  Time (min)   Mean    SD       *n*
  ------------ ------- -------- -----
  5            86.72   17.080   25
  10           87.60   14.224   25
  15           89.04   11.710   25
  20           86.96   14.058   25
  25           85.80   15.532   25
  30           83.64   15.223   25
  35           81.20   13.919   25
  40           79.52   15.075   25
  45           80.12   13.305   25
  50           80.52   12.836   25
  55           82.08   11.471   25
  60           80.28   10.998   25
  65           79.08   9.300    25
  70           77.00   11.091   25
  75           77.04   9.199    25
  80           76.72   7.619    25
  85           77.92   6.116    25
  90           78.04   5.955    25

SD=Standard deviation

###### 

Descriptive statistics of systolic blood pressure

  Time (min)   Mean systolic blood (mm of Hg)   SD       Number of patients
  ------------ -------------------------------- -------- --------------------
  10           117.32                           4.516    25
  20           120.48                           4.691    25
  30           116.96                           7.419    25
  40           120.12                           10.549   25
  50           120.56                           9.548    25
  60           119.92                           8.129    25
  80           119.24                           6.240    25
  90           117.64                           4.769    25

SD=Standard deviation

###### 

Descriptive statistics of diastolic blood pressure

  Time (min)   Mean    SD       *n*
  ------------ ------- -------- -----
  10           78.56   5.781    25
  20           79.24   5.109    25
  30           79.04   4.067    25
  40           78.96   5.248    25
  50           78.08   4.991    25
  60           73.20   16.161   25
  80           78.40   5.041    25
  90           77.76   3.574    25

SD=Standard deviation

###### 

Descriptive statistics of oxygen saturation

  Time (min)   Mean    SD      *n*
  ------------ ------- ------- -----
  5            98.00   0.500   25
  10           97.96   0.455   25
  15           98.00   0.500   25
  20           98.00   1.500   25
  25           98.80   0.408   25
  30           98.72   0.458   25
  35           98.16   0.473   25
  40           97.96   0.351   25
  45           98.12   0.726   25
  50           97.96   0.539   25
  55           97.48   0.918   25
  60           97.48   0.770   25
  65           97.84   0.473   25
  70           97.96   0.676   25
  75           97.68   0.690   25
  80           97.96   0.455   25
  85           97.96   0.455   25
  90           98.36   0.995   25

SD=Standard deviation

![Gender distribution](AMS-9-89-g003){#F3}

![Results of ramsay sedation score](AMS-9-89-g004){#F4}

![Results of OAA/S score](AMS-9-89-g005){#F5}

![Respiratory rate variation](AMS-9-89-g006){#F6}

![Systolic blood pressure variation](AMS-9-89-g007){#F7}

![Diastolic blood pressure b variation](AMS-9-89-g008){#F8}

![Heart rate variation](AMS-9-89-g009){#F9}

![Oxygen saturation variation](AMS-9-89-g010){#F10}

The statistical software used was SPSS 20.0 for Windows (SPSS, Chicago, IL, USA). Data were expressed as mean and standard deviation or number (percentages). Sedation and behavior scores were analyzed by proportions. Hemodynamic variables including HR, SpO~2~, and BP and respiratory rate were analyzed by repeated measures ANOVA. When a significant result was obtained, the Tukey test was applied for *post hoc* pairwise comparisons. *P* \< 0.05 was considered as statistically significant. All the parameters were recorded at a set interval of time. The primary outcome variable, i.e., the depth of sedation was measured using Ramsay sedation score and OAA/S. [Table 1](#T1){ref-type="table"} shows the Ramsay sedation score.

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

This study evaluated the efficacy of the intranasal administration of atomized dexmedetomidine to sedate adult patients undergoing minor oral surgical procedures. The level of sedation required was moderate as per ASA classification of sedation. The majority of patients receiving dexmedetomidine as a primary therapy experience clinically effective sedation yet were still easily arousable, a unique feature not observed with other clinically available sedatives.\[[@ref5]\]

Site of action of dexmedetomidine is in the locus coeruleus of the central nervous system, where it induces a state similar to natural sleep. Therefore, it is not surprising that external stimulation should facilitate arousal. Previous studies utilizing intranasal sedatives have primarily involved pediatric populations or noncompliant mentally disabled adults. These studies were primarily comparative studies comparing dexmedetomidine to other sedative drugs.\[[@ref6]\] Our study is one of these few that involve adult patients and that too in the field of oral and maxillofacial surgery.

In our study, we have used the drug in a diluted form. Some researchers attributed the failure of their studies to the use of diluted dexmedetomidine. It has been further concluded in a number of studies that a more standardized approach to preparation and delivery of the drug will increase the success rate.\[[@ref7][@ref8]\] Yuen *et al.* in 2012\[[@ref9]\] conferred that if a dose of 1 μg/kg is chosen, the onset time will range from 25 to 45 min with a median duration of sedative effect of 55--100 min. Cheung *et al.* in their study observed that the onset of clinical sedation was at 30--45 min after intranasal administration; so, they suggested that the drug should be given 45--60 min before a surgical procedure, which in their study was third molar surgery.\[[@ref4]\]

In our study, the sedative effect commenced only after 45 min; so, the time of delivering of the drug was set as 45 min before surgery. We observed that moderate sedation was achieved with the drug, and the sedation status of the patients was close to baseline around 90 min; all the patients were easily aroused by external stimuli. A sedative duration of 90 min was sufficiently long to perform a minor oral surgical procedure, and the short recovery period was convenient for outpatient dental sedation purposes. In our study, the vital statistics was closely monitored. These included HR, respiratory rate, SpO~2~, and BP. Yuen *et al.* 2012\[[@ref9]\] in their study used 1 g/kg and 1.5 mg/kg of dexmedetomidine intranasally and found no severe bradycardia or conduction abnormality on electrocardiogram monitoring. The observed hemodynamic changes did not induce any subjective symptoms. Gertler *et al.* observed that dexmedetomidine does not appear to have any direct effects on the heart. Dexmedetomidine could result in cardiovascular depression, i.e., bradycardia and hypotension in IV form if given in high doses.\[[@ref5]\] In our study, we observed that the HR ranged from 76 to 90 bpm approximately. The baseline HR was 86 approximately. The tachycardia was attributed to the anxiety of the patient before the procedure, as we did not give any anxiolytic drug preoperatively. A few times during the procedure if there was any discomfort to the patient due to the procedure, the HR was seen to have increased insignificantly. However at no time during the procedure any intervention was required. Dexmedetomidine, as a sedative agent, can provide easily controllable sedation without respiratory depression.\[[@ref10]\] Lack of respiratory depression due to dexmedetomidine is one of its major advantages. We, in our study, concluded that dexmedetomidine has no deleterious clinical effects on respiration when used in doses that are sufficient to provide adequate sedation and effective analgesia in the surgical population. As far as sedation with IV dexmedetomidine few studies showed a decrease up to 92%, in that case oxygen was given through face mask or nasal prongs.\[[@ref10]\] The adverse effects of the drug on SpO~2~ find a mention in a few animal studies that included rabbits.\[[@ref11]\] Furthermore, the studies using IV dexmedetomidine to give bolus doses like 6 ug/kg/h showed significant decrease in comparison to the pretreatment levels.\[[@ref12]\] Although in literature there was not a single study that showed that intranasal dexmedetomidine has any adverse effect on the SpO~2~ at doses ranging up to 2 ug/kg. In our study, we did not observe any decrease in the SpO~2~, and the need to give oxygen never rose. Furthermore, whether the SpO~2~ was altered or not, oxygen cylinder was kept handy even when giving low doses of dexmedetomidine.

The adverse effects of dexmedetomidine include hypotension, hypertension, nausea, bradycardia, atrial fibrillation, and hypoxia. Overdose may cause first-degree or second-degree atrioventricular block. These are the effects seen with IV route of administration, and no such effects have been seen with the use of intranasal dexmedetomidine. The same was observed in our study as well, i.e., no adverse effects on BP were observed. Due to its significant properties as sedative and analgesic and safe respiratory profile, coupled with its ease of use and antisialagogue properties, dexmedetomidine was thought to be very useful in dental/oral procedures.\[[@ref13]\] All effects of dexmedetomidine could be antagonized easily by administering the α2-adrenoceptor antagonist atipamezole, which, like dexmedetomidine, reverses sedation and sympatholysis and has a half-life of 1.5--2 h. With the increase in the minor oral surgical procedures, there is a huge discrepancy in the anesthetist patient ratio, with patients being more than the anesthetist. To assist in this process, the American Society of Anesthesiologists developed Guidelines for Sedation and Analgesia by nonanesthesiologists.\[[@ref14]\] This technique of using dexmedetomidine may be easily adaptable for use by properly trained nonanesthesiologists and nurse practitioners.\[[@ref15]\]

###### 

Measure: Systolic blood pressure

  Source                           Type III sum of squares   df      Mean square   *F*     Significant
  -------------------------------- ------------------------- ------- ------------- ------- -------------
  Factor 1: Greenhouse - Geisser   390.220                   2.534   153.985       3.172   0.038

Sum of squares and mean squares of the values recorded are a part of the calculation of the test value denoted by "*F*". "df" stands for degrees of freedom. The number of degrees of freedom is the number of values in the final calculation of a statistic that are free to vary

###### 

Measure: Respiratory rate

  Source                           Type III sum of squares   df      Mean square   *F*     *P* (significant IF \<0.05)
  -------------------------------- ------------------------- ------- ------------- ------- -----------------------------
  Factor 1: Greenhouse - Geisser   33.209                    4.115   8.069         1.828   0.127

Sum of squares and mean squares of the values recorded are a part of the calculation of the test value denoted by "*F*". "df" stands for degrees of freedom. The number of degrees of freedom is the number of values in the final calculation of a statistic that are free to vary

###### 

Measure: Diastolic blood pressure

  Source                           Type III sum of squares   df      Mean square   *F*     Significant
  -------------------------------- ------------------------- ------- ------------- ------- -------------
  Factor 1: Greenhouse - Geisser   676.155                   1.872   361.181       2.064   0.142

Sum of squares and mean squares of the values recorded are a part of the calculation of the test value denoted by "*F*". "df" stands for degrees of freedom. The number of degrees of freedom is the number of values in the final calculation of a statistic that are free to vary

###### 

Measure: Heart rate

  Source                           Type III sum of squares   df      Mean square   *F*      *P* (significant IF \<0.05)
  -------------------------------- ------------------------- ------- ------------- -------- -----------------------------
  Factor 1: Greenhouse - Geisser   6905.920                  3.375   2046.442      14.291   \<0.001

Sum of squares and mean squares of the values recorded are a part of the calculation of the test value denoted by "*F*". "df" stands for degrees of freedom. The number of degrees of freedom is the number of values in the final calculation of a statistic that are free to vary

###### 

Measure: SpO~2~

  Source                           Type III sum of squares   df      Mean square   *F*      Significant
  -------------------------------- ------------------------- ------- ------------- -------- -------------
  Factor 1: Greenhouse - Geisser   49.938                    5.383   9.278         10.151   \<0.001

Sum of squares and mean squares of the values recorded are a part of the calculation of the test value denoted by "*F*". "df" stands for degrees of freedom. The number of degrees of freedom is the number of values in the final calculation of a statistic that are free to vary

C[ONCLUSION]{.smallcaps} {#sec1-5}
========================

In conclusion, intranasal administration of 1.5 mg/kg atomized dexmedetomidine was clinically effective, convenient, and safe for the sedation of patients undergoing minor oral surgical procedures.
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